Shane R Stecklein
Affiliations: | The University of Kansas Cancer Center |
Area:
Breast Cancer, Lymphoma, Radiation BiologyGoogle:
"Shane Stecklein"Parents
Sign in to add mentor| Fariba Behbod | grad student | 2012 | University of Kansas (Cell Biology Tree) | |
| (Thesis:"Identification, exploitation and manipulation of BRCA1-dependent dna double-strand break and interstrand crosslink repair in breast and ovarian cancer therapy") | ||||
| Roy A. Jensen | grad student | 2012 | University of Kansas (Microtree) | |
| (Thesis:"Identification, exploitation and manipulation of BRCA1-dependent dna double-strand break and interstrand crosslink repair in breast and ovarian cancer therapy".) | ||||
| Wendy Ann Woodward | post-doc | The University of Texas MD Anderson Cancer Center | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Martín M, Yoder R, Salgado R, et al. (2024) Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Sharma P, Stecklein SR, Yoder R, et al. (2023) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. Jama Oncology |
| Stecklein SR, Barlow W, Pusztai L, et al. (2023) Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. Jco Precision Oncology. 7: e2300197 |
| Machiels M, Oulkadi R, Tramm T, et al. (2023) Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers. Breast (Edinburgh, Scotland). 71: 13-21 |
| Jagsi R, Barlow WE, Woodward WA, et al. (2023) Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. Jama Oncology |
| Stecklein SR, Kimler BF, Yoder R, et al. (2023) ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. Npj Breast Cancer. 9: 10 |
| Subham S, Jeppson JD, Worcester C, et al. (2022) EGFR as a potent CAR T target in triple negative breast cancer brain metastases. Breast Cancer Research and Treatment |
| Yoder R, Kimler BF, Staley JM, et al. (2022) Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. Npj Breast Cancer. 8: 80 |
| Abuhadra N, Stecklein S, Sharma P, et al. (2022) Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies. The Oncologist. 27: 30-39 |
| Chapman BV, Liu D, Shen Y, et al. (2021) Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. International Journal of Radiation Oncology, Biology, Physics |